S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
5 Game-Changing Cheap Stocks (Ad)pixel
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
5 Game-Changing Cheap Stocks (Ad)pixel
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
A One Stop Shop for Everything Futures Trading (Ad)pixel
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
5 Game-Changing Cheap Stocks (Ad)pixel
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
5 Game-Changing Cheap Stocks (Ad)pixel
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
A One Stop Shop for Everything Futures Trading (Ad)pixel
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
5 Game-Changing Cheap Stocks (Ad)pixel
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
5 Game-Changing Cheap Stocks (Ad)pixel
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
A One Stop Shop for Everything Futures Trading (Ad)pixel
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
5 Game-Changing Cheap Stocks (Ad)pixel
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
5 Game-Changing Cheap Stocks (Ad)pixel
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
A One Stop Shop for Everything Futures Trading (Ad)pixel
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
NASDAQ:EXAS

Exact Sciences - EXAS Stock Forecast, Price & News

$33.30
+0.81 (+2.49%)
(As of 10/3/2022 12:00 AM ET)
Add
Compare
Today's Range
$32.00
$33.82
50-Day Range
$31.97
$49.37
52-Week Range
$31.62
$104.50
Volume
1.73 million shs
Average Volume
2.16 million shs
Market Capitalization
$5.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$69.14

Exact Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
107.6% Upside
$69.14 Price Target
Short Interest
Bearish
6.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
1.13mentions of Exact Sciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$208,005 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.22) to ($3.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

198th out of 1,093 stocks

Medical Laboratories Industry

7th out of 30 stocks

EXAS stock logo

About Exact Sciences (NASDAQ:EXAS) Stock

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Stock News Headlines

Is Illumina Still the Gamechanger in Genomics Sequencing? (EXAS)
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused
Would Exact Sciences Acquire Invitae? Unlikely.
Here's Why Investors Should Hold Exact Sciences (EXAS) Stock
EXAS Exact Sciences Corporation
EXAS October 28th Options Begin Trading
Exact Sciences: Don't Deem It Guilty by Association
What 9 Analyst Ratings Have To Say About Exact Sciences
Here's Why You Should Retain Exact Sciences (EXAS) Now
Ginkgo Bioworks is Toying With Wall Street
Exact Sciences (EXAS) Q2 2022 Earnings Call Transcript
See More Headlines
Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Company Calendar

Last Earnings
8/02/2022
Today
10/03/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXAS
CUSIP
30063P10
Employees
6,500
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$69.14
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+107.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-595,630,000.00
Pretax Margin
-38.51%

Debt

Sales & Book Value

Annual Sales
$1.77 billion
Book Value
$19.66 per share

Miscellaneous

Free Float
174,660,000
Market Cap
$5.89 billion
Optionable
Optionable
Beta
1.34

Social Links


Key Executives

  • Mr. Kevin T. ConroyMr. Kevin T. Conroy (Age 56)
    Chairman of The Board & CEO
    Comp: $2.37M
  • Mr. Jeffrey T. Elliott CFA (Age 44)
    Exec. VP, CFO & COO
    Comp: $904.67k
  • Mr. D. Scott CowardMr. D. Scott Coward (Age 57)
    Chief Legal Officer
    Comp: $847.28k
  • Mr. Graham P. LidgardMr. Graham P. Lidgard (Age 73)
    Emeritus Chief Science Officer
    Comp: $937.04k
  • Mr. Everett V. Cunningham (Age 56)
    Chief Commercial Officer
    Comp: $1.01M
  • Dr. Jorge A. Garces Ph.D. (Age 50)
    Chief Science Officer
  • Mr. Sri Kalluri
    Chief Information Officer
  • Ms. Megan Jones
    Associate Mang. of Investor Relations
  • Mr. Tim Caprez
    Chief Compliance Counsel & VP
  • Mr. Vic Parker
    Head of Sales













EXAS Stock - Frequently Asked Questions

Should I buy or sell Exact Sciences stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EXAS shares.
View EXAS analyst ratings
or view top-rated stocks.

What is Exact Sciences' stock price forecast for 2022?

12 brokerages have issued twelve-month target prices for Exact Sciences' stock. Their EXAS share price forecasts range from $40.00 to $130.00. On average, they predict the company's share price to reach $69.14 in the next twelve months. This suggests a possible upside of 107.6% from the stock's current price.
View analysts price targets for EXAS
or view top-rated stocks among Wall Street analysts.

How have EXAS shares performed in 2022?

Exact Sciences' stock was trading at $77.83 at the beginning of the year. Since then, EXAS stock has decreased by 57.2% and is now trading at $33.30.
View the best growth stocks for 2022 here
.

When is Exact Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our EXAS earnings forecast
.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings results on Tuesday, August, 2nd. The medical research company reported ($0.94) earnings per share for the quarter, beating analysts' consensus estimates of ($1.07) by $0.13. The medical research company earned $521.64 million during the quarter, compared to analyst estimates of $496.75 million. Exact Sciences had a negative net margin of 37.90% and a negative trailing twelve-month return on equity of 22.07%.

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.98 billion-$2.02 billion, compared to the consensus revenue estimate of $2.02 billion.

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How do I buy shares of Exact Sciences?

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $33.30.

How much money does Exact Sciences make?

Exact Sciences (NASDAQ:EXAS) has a market capitalization of $5.89 billion and generates $1.77 billion in revenue each year. The medical research company earns $-595,630,000.00 in net income (profit) each year or ($4.23) on an earnings per share basis.

How many employees does Exact Sciences have?

The company employs 6,500 workers across the globe.

Does Exact Sciences have any subsidiaries?
The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..
Read More
How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701.

This page (NASDAQ:EXAS) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.